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OBJECTIVES: To assess demographic and clinical factors associated with statin
selection among patients in a large employer-based claims database. METHODS:
This study examined predictors of statin selection among statin users whowere 18
to 64 years old and initiated pravastatin (PS) vs. simvastatin (SS), atorvastatin (AS),
or rosuvastatin (RS) between 1/1/2007 and 12/31/2007. Index statin use was defined
as the first statin claim following at least 90 days of no statin access. Multiple
logistic regression models were employed to assess predictive factors of PS initia-
tion versus other statin initiations. RESULTS: Of the total 1,336,433 statin users
identified, there were 14,122 PS initiators, 66,156 AS initiators, 27,062 RS initiators,
and 77,180 SS initiators. Compared to other statin users, patients initiating PSwere
older (PS: 54.0, SS: 53.3, AS: 53.9, RS: 53.5, P0.01) and more likely to be female (PS:
52.3%, SS: 47.6%, AS: 45.4%, RS: 47.0%, P0.01). A higher percentage of PS initiators
had diabetes (PS: 20.1%, SS: 17.9%, AS: 17.9%, RS: 18.3%, P0.01), liver disease (PS:
2.7%, SS: 1.9%, AS: 2.1%, RS: 2.4%, P0.01), human immunodeficiency virus infec-
tion (HIV) (PS: 0.7%, SS: 0.1%, AS: 0.3%, RS: 0.3%, P0.01), and hypertension (PS:
45.1%, SS: 40.8%, AS: 41.1%, RS: 43.9%, P0.01) in the baseline period. After control-
ling for demographic and clinical characteristics, older age, female gender, history
of diabetes, liver disease, HIV, and hypertension were significant predictors of PS
initiation. Other predictors of PS initiation included use of calcium channel block-
ers, ezetimibe, fenofibrates, and protease inhibitors over the 1-year pre-index pe-
riod. Primary care physician (PCP) as the prescriber was positively associated with
initiating PS compared to RS or SS.CONCLUSIONS:The analyses indicate that older
age, female gender, presence of selected comorbidities, prior use of certain medi-
cations, and PCP as prescriber are predictors of PS initiation among working age,
commercially insured patients.
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OBJECTIVES: Cardiovascular diseases are the major health problem and adequate
therapy, which includes usage of beta blockers (ATC, C07) and diuretics (ATC, C03),
leads to reduction of cardiovascular morbidity andmortality. The aim of our study
was to identify and analyze changes in the usage of these drugs in Croatia and
Slovenia from 2000-2008 and to identify the rate of the generic drugs usage as well
as the average price for 1 DDD.METHODS: The data concerning consumption have
been obtained from the International Medical Statistics database for Croatia and
they are presented in defined daily doses per 1000 inhabitants per day (DDD/1000).
Financial expenditure data are presented in Euros and the average cost per DDD
was calculated for each drug group. RESULTS: The total usage of diuretics is on
average 19% higher in Croatia and continually increasing in both countries. Con-
sumption rate of furosemid among diuretics is lower in Slovenia (43.96% in 2008),
while in Croatia 67.28% (2008). The generic drugs usage is higher in Croatia during
the whole investigated period, e.g. in 2008, 87.4 % of all prescribed diuretics were
generics in Croatia, and in Slovenia 59.4%. The average price per 1 DDD was more
than twice lower in Croatia (0.08 EUR/DDD vs. 0.17 EUR/DDD in Slovenia). The beta
blockers drugs usage is 13% higher in Slovenia, but generic drugs usage is higher in
Croatia. CONCLUSIONS: Increased diuretics and beta blockers drug usage is com-
parable to worldwide trends, but drug prescribing patterns are different when
comparing both countries. Although the generic drugs usage is relatively high in
Croatia, it should be further supported and promoted. According to our investiga-
tion there is a possibility for further price reduction of diuretics and beta blockers in
Slovenia. This is important as a tool to decrease costs of healthcare systems.
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OBJECTIVES: To estimate 2003 point prevalence, treatment and control rates of
hypertension for different age groups of primary care attendees in Germany, to
examine factors associated with pharmacotherapy and adequate blood pressure
control and to examine whether changes have occurred in rates of treatment and
control since 2001. METHODS: Using standardized clinical diagnostic and treat-
ment appraisal forms, blood pressure levels and patient questionnaires for 55,518
participants from the DETECT study (2003) were analyzed. RESULTS: According to
physician diagnosis overall prevalence was 35.5%, according to NHANES criteria
56.0%. Among those defined by NHANES criteria, treatment and control rates were
56.0% and 20.3%, respectively. Significant predictors for receiving antihypertensive
medication were: increasing age, female sex, obesity, previous myocardial infarc-
tion and the prevalence of comorbid conditions such as CHD, dyslipidemia and
diabetes mellitus. Significant positive predictors of adequate blood pressure con-
trol were CHD and antihypertensive medication. Inadequate control was associ-
atedwith increasing age, male sex and obesity. As compared to findings from 2001,
rates of treatment and control indicate some improvement across all age groups.
CONCLUSIONS:Rates of treated and controlled hypertension according toNHANES
criteria in DETECT remain considerably low as compared to the rates of 2001,
despite consistent indications of some improvement. Hypertensive patients with
risk factors such as obesity and associated comorbidities such as CHD, dyslipide-
mia and diabetes weremore likely to receive antihypertensive drugs in accordance
with guidelines. Adequate blood pressure control was achieved in more patients
with obesity and CHD, but not those with diabetes mellitus or dyslipidemia.
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OBJECTIVES: To compare health care expenditures of hypertensive patients on
metoprolol tartarate (MT) andmetoprolol succinate (MS).Metoprolol, a selective -1
blocker, is available in two different salt forms in themarket-metoprolol succinate
(MS) and metoprolol tartarate (MT). Both of these salts are FDA approved for the
treatment of hypertension. Several studies have shown similar efficacies between
the two salts; however they are priced at different levels because of their pharma-
cokinetic properties. MT is the short acting salt and is given twice daily, whereas
MS is the long acting salt and is given once daily. METHODS: Two cohorts of pa-
tients usingMT andMSwere selected from 2008Medical Expenditure Panel Survey
(MEPS). Propensity score (PS) matching technique was used to balance the cohorts
on various parameters such as demographic information, insurance status and
comorbity score. Patients using MTwerematched to patients using MS on the logit
of propensity score using calipers of width equal to 0.2 of the standard deviation of
the logit of the propensity score. To estimate mean expenditure costs and 95%
confidence intervals, non parametric bootstrap sampling method was used.
RESULTS: A total of 742 patients were found to use metoprolol (MT-388, MS- 354).
After PS matching, a total of 594 patients were left in the sample for final analysis
(298 patients in each cohort). The average annual expenditure in two groups did not
differ significantly. After carrying out non parametric bootstrap sampling using
1,000 samples, MT cohort had $10,779 (95% CI: $10,682- $10,875) average annual
expenditure while MS cohort had $9,810 (95% CI: $9,810-$10,003). CONCLUSIONS:
Both the salts of Metoprolol were found have similar average annual total health-
care expenditure, however once a daily salt (MS) has higher out of pocket cost.
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OBJECTIVES: ASA/AHA guidelines for stroke prevention in patients with non-val-
vular atrial fibrillation (NVAF) recommend anticoagulant (AC) therapy with a vita-
min K antagonist (e.g., warfarin) for patients without hemorrhagic contraindica-
tion. Bridging with low molecular weight heparin (LMWH) was recently added to
these guidelines (Class IIa), butwith little supportive evidence (Level of Evidence C).
Little is known about the use of AC therapy in the inpatient setting and how it
relates to hospital length of stay (LOS).METHODS: Patientswith anNVAF discharge
diagnosis between 7/1/04-9/30/09 were identified from administrative claims data
representing over a hundred US hospitals. Inpatient AC use by drug type was re-
ported to identify patients receiving warfarin alone and in combination with
LMWH/pentasaccharide (PS) or unfractionated heparin (UFH), indicative of bridg-
ing. LOS was measured and reported by AC combinations. Non-parametric statis-
tical tests were used to compare LOS among patients receiving warfarin only to
thosewith bridge therapy.RESULTS:Of 6340NVAFpatients, 76% received inpatient
AC therapy, with 3037 (48%) receiving warfarin. Of patients receiving warfarin, 64%
were bridged with another AC. LMWH/PS was themost common bridge agent (45%
of all bridged patients), followed byUFH (36%), and by LMWH/PS andUFH combined
(18%). The mean LOS for patients receiving bridge therapies was 6.3 days (SD6.1)
compared to 4.2 days (SD 3.1) for warfarin alone, p.0001. By bridging drug type,
mean LOS was 5.6 days (SD5.3) for LMWH/PS; 6.0 days (SD4.9) for UFH, and 8.4
days (SD8.4) for LMWH/PS and UFH. CONCLUSIONS: Less than half of all NVAF
patients receivedwarfarinwhile hospitalized. Among those takingwarfarin, bridg-
ing with other anticoagulants was common and was associated with longer LOS
than patients receiving warfarin alone.
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OBJECTIVES: Electronic Medical Records often lack accurate problem lists. The
objectives of this studywere to examine if alerts requesting indication information
during order entry of medications used to treat a common disease, hypertension,
can improve problem lists. METHODS: Inpatient orders generated by previously
implemented clinical decision support (CDS) in an academic hospital using CPOE
were reviewed. CDSwas developed for classes of antihypertensive and 3 additional
diagnoses: CHF, benign prostatic hypertrophy and nephropathy. Five logical med-
ication groups were developed. A random sample of 250 charts were collected for
each medication group and reviewed by physicians to determine alert yield and
added problem accuracy. The accuracy and yield (problems added per order) were
analyzed across the medication groups, clinician types, and clinical venues.
RESULTS: Preliminary results obtained from the group of medications that only
treat HTN and no other diagnoses (HTN group) showed an accuracy of additions to
the problem list of 92% and the yield, was 76%. For the group of medications which
treated HTN and CHF (CHF group), the accuracy and yield were lower, 81% and 62%
respectively. Looking at the HTN group alone, the accuracy was 100% for attending
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physicians and 55% for residents physicians. Similarly the accuracy was higher in
the ambulatory setting than for inpatient, 89% vs. 62%. The yield for the HTN group
was also higher with attendings than residents, 100% vs. 67%, and the yield was
higher in ambulatory versus inpatient settings, 87% vs. 64%. CONCLUSIONS: CDS
based onmedication orders during CPOEmay improve problem lists. The accuracy
and yield of diagnostic information is sensitive to medication type, clinical venue
and possibly clinician type. Mandatory indication based prescribing may not pro-
duce very accurate indication data. There is a substantial need for further research
in this area.
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OBJECTIVES: Treatment strategies for atrial fibrillation (AF) are classified into rate
control and rhythm control. They can be employed through the use of pharmaco-
logical and non-pharmacological approaches. This study described the trend in the
utilization of treatment strategies for the management of AF in newly diagnosed
patients between 1999 and 2008.METHODS: The study was a retrospective cohort
study of administrative claims data from a large nationally dispersed group of
commercially insured subjects from 1999-2008. Newly diagnosed AF patients aged
18 years and with at least one claim for an AF related intervention within 12
months of diagnosis were identified. Based on initial treatment received, patients
were classified in pharmacotherapy or non-pharmacotherapy treatment groups.
Patients initiated on drug-therapies were classified into rate-control (beta-blocker,
calcium channel blocker or digoxin) or rhythm control groups. Descriptive analysis
was conducted to compare the patient demographic characteristics across the
treatment groups. OLS regressionwas conducted to assess linear trends. RESULTS:
Of the 6284 newly diagnosed AF patients who received treatment within one-year,
83.7% underwent pharmacotherapy as the 1st line therapy. Majority (86.3%) of pa-
tients who initiated drug therapy received rate-control medications only. Relative
distribution of different treatments across timedid not vary significantly. However,
within rate-control group, beta-blockers use increased significantly (p 0.0001)
from 47.5% (1999) to 70.58% (2008), whereas use of calcium channel blockers and
digoxin decreased. Non-pharmacotherapy was employed more commonly in the
mid-west (44.95%, p0.0002), in patients younger than 65 years (58.35%, p0.0001)
and its use decreased with increasing age. Males were more likely to undergo
non-pharmacotherapy (69.9%, p 0.0001). CONCLUSIONS: Higher utilization of
rate control as 1st line therapy compared to other treatment strategies is consistent
with the current literature. Greater use of non-pharmacotherapy in younger pa-
tients can be partially explained by the higher success rate in this population.
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BACKGROUND: In the current statin landscape, a need has emerged for simple and
less data-intensive tools to identify patients at risk for cardiovascular events and to
appropriately identify patients for higher-efficacy statin use. OBJECTIVES: To ex-
amine the feasibility of a pharmacy-based algorithm as amarker of cardiovascular
risk to guide appropriate statin selection at the point of service. METHODS: A
retrospective analysis using an integrated database of over 70 pooled health plans
was conducted for the period 2003 to mid-2010. Patients on at least one cardiovas-
cular medication of interest (N 4,276,418) and18 years old werematched by age
and gender to control subjects (not on cardiovascular medications [N 3,046,021]).
Cardiovascular medications included were antihypertensive, antidiabetic, anti-
anginal, antiarrhythmic, anticoagulant, non-statin lipid modifier, and antiplatelet
drugs. Subjects’ cardiovascular risk status (high/moderate/low) was assessed ac-
cording to the current National Cholesterol Education Program guidelines, from
records of diagnoses and procedures. Relative risks were calculated for the likeli-
hood of being at increased risk (high or moderate risk status) as the ratio of pro-
portions of patients on cardiovascular medication versus controls who were at
increased risk. RESULTS: The study population had amean age of 53 years. Overall,
a patient receiving any cardiovascularmedicationwas 2.4 timesmore likely to be at
increased risk (95%CI 2.39,2.40) and was 2.7 times more likely to experience a car-
diovascular event (95%CI 2.73,2.74) than a subject not receiving any cardiovascular
medication. Additionally, it was observed that 27% of the total patients in the
health plans who were on cardiovascular medications accounted for 71.5% of all
cardiovascular events in that group. CONCLUSIONS: A pharmacy algorithm based
on usage of various cardiovascular medications can be used to identify increased
cardiovascular risk. These initial findings demonstrate the potential of using
widely available cardiovascular prescription data in designing statin formulary
management strategies.
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OBJECTIVES: Electronicmedical records (EMRs) increasingly are being used by out-
comes researchers to study the quality of medical care. The study assessed the
impact of non-medical switches in ARB therapy on blood pressure (BP) andmedical
resource utilization including office visits and other antihypertensivemedications.
METHODS: A retrospective study was conducted using the GE Centricity EMR of a
primary care physicians group. Hypertensive patients18 years, continuously en-
rolled, and receiving ARB therapy were included. Switch must have occurred after
the patient was on the first ARB for at least 60 days. The control group remained on
the sameARBanddid not switch. A 1:1matchingwas done on the duration of initial
ARB therapy and presence of diabetes or renal impairment. Demographic charac-
teristics, clinical parameters, ARB use, and office visits were identified. Data was
extracted using Microsoft SQL and statistical analyses were conducted using SPSS
version 18.0. RESULTS: A total of 4,851 patients (mean age 68.23 years, female
58.1%) were prescribed an ARB between 2004 and 2008 out of which 3,083 (63.6%)
stayed on one ARB and 1,768 (36.4%) switched from one ARB to another. Matched
pairs of switchers (n357) and control group (n357) were then identified. There
was no difference in mean baseline systolic BP (SBP) for switchers (143.7921.22)
and control (144.2022.16) but switchers had higher post-switch SBP
(141.0618.52) than control (137.9720.58) (p0.035). More switchers lost control
from index to first visit post-index period (11.5%) than control (8.7%). More antihy-
pertensive agents were added in switchers (1.911.7) than control (1.021.2) in the
post-index period (p0.001). CONCLUSIONS: EMRs have the potential to bridge
research with clinical care by providing real-world data. This study demonstrates
that non-medical switches may result in loss of BP control and additional medical
resource use. Thus, careful consideration should be given before switching thera-
pies for non-medical reasons.
PCV99
MEDICAL RESOURCE UTILIZATION AND COSTS FOLLOWING HOSPITALIZATION
OF PATIENTS WITH CHRONIC HEART FAILURE IN THE UNITED STATES
Korves C1, Eldar-Lissai A1, Rodermund D1, Swallow E1, Cummings AK1, Ariely R2,
Duh MS1
1Analysis Group, Inc., Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover,
NJ, USA
OBJECTIVES: The study objective was to determine medical resource utilization
and direct and indirect costs following hospitalization with chronic heart failure
(HF). METHODS: Patients with 1 hospitalization with a chronic HF claim (ICD-9
428.22, 428.32 or 428.42) were identified in a US commercial insurance claims da-
tabase from 2004-2008. Patients were observed from beginning of first hospitaliza-
tion (index hospitalization) for chronic HF until disenrollment or end of data avail-
ability. Inpatient, outpatient, and prescription drug data were used to estimate per
patient per month (PPPM) utilization rates. Costs (2009 USD) were calculated per
hospitalization and PPPM for patients65 years, and included insurers’ reimburse-
ment, patient out-of-pocket and sick leave costs. RESULTS: There were 7,814 pa-
tients (mean age 73.2 years, 55.7% male) meeting inclusion criteria. Mean HF hos-
pitalization length of stay increased from 6.7 days at index hospitalization to 8.2
days at fourth re-hospitalization. Rate of HF-related re-hospitalization remained
over 0.045 PPPM throughout 24 months of follow-up, accounting for over 78% of
all-cause hospitalizations. Rate of all-cause and HF-related outpatient visits
peaked at 4.0 and 0.59 visits PPPM, respectively, within the three months after
index hospitalization. Index hospitalization was most expensive (direct medical
costs$31,998). Patient out-of-pocket costs accounted for less than 10% of direct
hospitalization costs and sick leave costs were less than $1,800 at any hospitaliza-
tion. During the study period, outpatient cardiovascular drugs accounted for a
small proportion of total pharmacy costs (approximately 20%); average PPPM cost
varied from $88 to $124, representing less than 1% of the average cost of a HF-
related hospitalization. CONCLUSIONS: Treating chronic HF patients is resource
intensive. The greatest utilization and cost burden occur within the three months
after index hospitalization and patients continue to be burdened after hospitaliza-
tion by high inpatient and outpatient visit rates.
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OBJECTIVES: 1) To determine costs and utilization incurred by employees follow-
ing enrollment in an employer-sponsoredmedication therapymanagement (MTM)
program and 2) to assess the impact of attrition on health care expenditures.
METHODS: A longitudinal study using medical claims. Study participants were
Lucas County employees with diabetes, hypertension and/or hyperlipidemia par-
ticipating in an employer-sponsored open-enrollment MTM program. Claims for
office, emergency roomand inpatient visitswere analyzed for the period of January
2005-July 2010. Disease-related expenditures were tracked for a period of two-year
pre- and post enrollment. All expenditures were calculated as average costs per-
patient pre and post joining and also as total expenditure borne by the employer.
Dropouts were identified from an appointment database. Expenditures were cal-
culated using claims for one year before and after the dropout date. RESULTS:
Claims were received for 361 employees that enrolled in the MTM program. Office
visit expenses went down by $71,442.29 or by 22.36% after joining the MTM pro-
gram. An increase in spending for emergency room visits by $12,597.16 was ob-
served, there were no recurring post-enrollment visits and those that occurred
were for indications that could have increased long-term spending for the em-
ployer. Total expenditure on inpatient visits went up by approximately $7600 but
the amount spent on each visit went down from $7,746.36  4,169.13 to 4,408.07 
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